Alzheimer’s Therapeutics Market

The Alzheimer’s disease therapeutics market is projected to witness significant expansion, supported by the anticipated launch of multiple emerging therapies. Key late- and mid-stage candidates include BioVie’s Bezisterim (NE3107), AB Science’s Masitinib (AB1010), Annovis Bio’s Buntanetap, Cassava Sciences’ Simufilam (PTI-125), TauRx Therapeutics’ Hydromethylthionine mesylate (TRx0237), Novo Nordisk’s Semaglutide (NN6535), and Eli Lilly’s Remternetug (LY3372993), among others. In parallel, several novel agents in earlier stages of clinical development continue to strengthen the pipeline.

Stay ahead of emerging Alzheimer’s therapies: https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

The Alzheimer’s disease market is expected to grow steadily, fueled by the potential commercialization of multiple innovative therapies targeting diverse disease mechanisms. Alongside late-stage candidates, a robust early-stage pipeline is under development, highlighting continued investment and scientific momentum in the field.

DelveInsight’s Alzheimer’s Disease Market Insights report offers an in-depth analysis of current treatment paradigms, emerging therapies, individual drug market shares, and historical as well as forecasted market size from 2020 to 2034 across the 7MM, which includes the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways from the Alzheimer’s Disease Market Report

• According to DelveInsight’s assessment, the Alzheimer’s disease market size across the 7MM was approximately USD 5 billion in 2024.
• The United States represented the largest share, accounting for nearly 50% of the total 7MM market in 2024, compared with EU4 countries, the UK, and Japan.
• In 2024, there were an estimated 15 million diagnosed prevalent cases of Alzheimer’s disease and nearly 100 million prevalent cases of preclinical Alzheimer’s disease across the 7MM. These figures are projected to rise consistently through 2034, driven by population aging and enhanced diagnostic capabilities.
• DelveInsight estimates indicate that the US alone had around 5.5 million diagnosed prevalent cases of agitation associated with Alzheimer’s disease in 2024.
• A wide range of companies—including Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Eisai, TauRx Therapeutics, Johnson & Johnson, and others—are actively advancing novel therapies expected to enter the Alzheimer’s disease market in the coming years.
• Prominent pipeline candidates include Masitinib (AB1010), Valiltramiprosate (ALZ-801), Mirodenafil (AR1001), Levetiracetam (AGB101), Blarcamesine (ANAVEX2-73), Buntanetap, Tricaprilin (CER0001), Bezisterim (NE3107), Semaglutide (NN6535), Remternetug (LY3372993), Masupirdine (SUVN-502), COBENFY (KarXT), IGC-AD1, T3D-959, LX 1001, AXS-05, ABvac40, E2814, HMTM/TRx0237, GV1001, ACI-35.030/JNJ-2056, LOMECEL-B, Pepinemab, SinaptiStim System, and others.

Alzheimer’s Disease Market Dynamics

The market dynamics for Alzheimer’s disease are expected to evolve substantially over the forecast period. Advances in structural and functional MRI, along with biomarker-driven diagnostics, have significantly improved insights into disease pathology. These developments have reinforced a diverse pipeline targeting amyloid deposition, tau pathology, neuroinflammation, and synaptic dysfunction, creating opportunities for innovative, cost-effective, and patient-friendly therapies.

The anticipated entry of therapies with improved efficacy profiles, combined with rising diagnosis rates, is expected to be a key driver of market growth across the 7MM. However, market expansion may be constrained by several challenges, including historically high clinical failure rates, complex disease biology, reliance on single-target strategies, and expensive diagnostic tools. Additionally, generic erosion of traditional drug classes, reimbursement hurdles, pricing pressures, workforce shortages, and persistent underdiagnosis may limit market uptake.

Explore DelveInsight’s complete Alzheimer’s Disease Market Insights report to uncover growth opportunities - https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

1. Eisai Co., Ltd. 

• Company & Country: Eisai Co., Ltd. (Japan)
• Drug Candidate: Lecanemab (marketed as LEQEMBI® / レケンビ®)
• Clinical Phase: Regulatory approval based on Phase III Clarity AD global trial data; launch/registration ongoing in Asia (including Korea).
• Mechanism of Action (MOA): Humanized monoclonal antibody binding amyloid-β (Aβ) protofibrils and fibrils, reducing brain Aβ deposits implicated in Alzheimer’s pathology.
• Latest Developments / Regulatory Updates:
  
  
• • LEQEMBI® was approved in South Korea in May 2024 for mild cognitive impairment due to AD and mild AD dementia, based on positive Phase III results demonstrating reduction in disease progression.
  • Subcutaneous formulation submission was filed with Japan’s PMDA (Nov 2025) to enable at-home dosing.
• Clinical Trial Registry IDs:
• • Clarity AD Phase III trial (global, including sites in Japan) data underpins approvals — typically: NCT03887455 (commonly cited for lecanemab; confirm via registry). (Note: specific Japan site entries can be found under that NCT number.)